Abstract Details

Title Clinical profile of African-American and Caucasian patients with Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P4 - Poster Session 4 (5:30 PM-6:30 PM)

Poster/Presentation
Number 9-010

Objective

To characterize clinical features of African-American (AA) and Caucasian (CA) patients with multiple sclerosis.

Background

A more severe disease course has been reported in AA in comparison with CA MS patients. Sociodemographic differences and limited access to treatment have been often used to explain the different disability profile in the two groups. To date, an objective assessment of disability in AA and potential differences with CA patients is still lacking.

Design/Methods

Fifty-one AA patients (40F, mean age 38.45 ± 11.13 yrs, mean disease duration 7.88 ± 5.39 yrs), 37 AA healthy controls (HC) (25F, mean age 35.97 ± 12.44 yrs), 43 CA patients (32F, mean age 39.00 ± 10.56 yrs, mean disease duration 6.67 ± 7.00 yrs) and 18 CA HC (12F, mean age 30.72 ± 6.94 yrs) were prospectively enrolled. In all subjects, an extensive neuropsychological and sensory-motor evaluation was performed. Each patient’s group was compared with a race-matched HC group via ANCOVA analysis, accounting for age, gender, years of education, estimated with the Wechsler Test of Adult Reading (WTAR) and socioeconomic status expressed as yearly income.

Results AA and CA patients did not differ in age, gender, disease duration, while they did differ in yearly income (p=0.008). When compared to their matched HC group, AA and CA patients showed similar deficits in information processing speed, attention, visuospatial memory, verbal fluency, ambulation and manual dexterity (p ranging from 0.049 to <0.0001). While CA showed an additional impairment of verbal memory (p=0.009), AA patients showed additional involvement of multitasking capability (p=0.018), motor speed and coordination, balance, strenght and sensitivity (p ranging from 0.046 to 0.001).

Conclusions

Even when accounting for sociodemographic features, AA patients show more severe and widespread disability than CA patients with MS.

Authors/Disclosures
Maria Petracca, PhD (University of Rome Sapienza) PRESENTER	Dr. Petracca has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Daniel P. Kurz, MD (University of Chicago)	An immediate family member of Dr. Kurz has received personal compensation for serving as an employee of Grainger. Dr. Kurz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Foundation for Sarcoidosis Research. An immediate family member of Dr. Kurz has or had stock in Grainger. The institution of Dr. Kurz has received research support from Biogen.
Claire Riley, MD, F�鶹��ýӳ��	Dr. Riley has received personal compensation for serving as an employee of AstraZeneca. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic AG. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cabaletta Bio. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics.
Jonathan Howard, MD (NYU Langone Health)	Dr. Howard has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MCE Conferences. Dr. Howard has received publishing royalties from a publication relating to health care. Dr. Howard has received publishing royalties from a publication relating to health care. Dr. Howard has received publishing royalties from a publication relating to health care. Dr. Howard has a non-compensated relationship as a Test writer with ABPN that is relevant to �鶹��ýӳ�� interests or activities.
Sylvia Klineova, MD (Icahn School of Medicine At Mount Sinai)	Dr. Klineova has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Klineova has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Klineova has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Klineova has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion.
Matilde Inglese, MD, PhD (University of Genoa)	Dr. Inglese has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for SANOFI GENZYME. Dr. Inglese has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOGEN. Dr. Inglese has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVARTIS. Dr. Inglese has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for MERCK-SERONO. Dr. Inglese has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Dr. Inglese has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MS Journal.

�鶹��ýӳ��

�鶹��ýӳ��